A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk's experimental drug amycretin shows promising results in early trials, aiding significant weight loss in ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...